FABP1 and colorectal cancer: Although current therapeutic strategies targeting the FABP family primarily involve suppressing their expression—seemingly contradictory to our observation of FABP1 downregulation in metastatic lymph nodes of gastric cancer—similar paradoxical findings have been reported for FABP1 in colorectal cancer [63,64].